Citius Oncology (CTOR) Net Equity Issued and Repurchased (2025 - 2026)

Citius Oncology's (CTOR) quarterly Net Equity Issued and Repurchased came in at -$61947.0 in Q1 2026, down 100.41% on a QoQ basis from $15.1 million in Q4 2025.

Citius Oncology (CTOR) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has 2 years of Net Equity Issued and Repurchased data on file, last reported at -$61947.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 500,000.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 23.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Citius Oncology 58.02 Mn 58.02 Mn 1.34 Mn -61,947.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -61,947.00
Mar 31, 2026 -61,947.00
Dec 31, 2025 15.13 Mn
Dec 31, 2025 15.13 Mn
Sep 30, 2025 15.17 Mn
Sep 30, 2025 15.17 Mn